DIAGNOS LABORATORIUM UTAMA TBKDD

DIAGNOS LABORATORIUM UTAMA TBK

199IDRD
−1−0.50%
As of today at 04:40 UTC
IDR
No trades
See on Supercharts

DGNS fundamentals

DIAGNOS LABORATORIUM UTAMA TBK financial statements, including revenue, expenses, profit, and loss

The total revenue of DGNS for the last quarter is 39.30 B IDR, and it's 5.86% lower compared to the previous quarter. The net income of Q2 24 is 940.04 M IDR.

Q1 '20
Q3 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
‪‪−17.00 B‬‬
‪0.00‬
‪‪17.00 B‬‬
‪‪34.00 B‬‬
‪‪51.00 B‬‬
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: IDR
Q1 '20
Mar 2020
Q3 '20
Sep 2020
Q1 '21
Mar 2021
Q2 '21
Jun 2021
Q3 '21
Sep 2021
Q4 '21
Dec 2021
Q1 '22
Mar 2022
Q2 '22
Jun 2022
Q3 '22
Sep 2022
Q4 '22
Dec 2022
Q1 '23
Mar 2023
Q2 '23
Jun 2023
Q3 '23
Sep 2023
Q4 '23
Dec 2023
Q1 '24
Mar 2024
Q2 '24
Jun 2024
TTM
Total revenueYoY growth
‪‪46.97 B‬‬
−42.75%
‪‪49.06 B‬‬
−4.46%
‪‪37.64 B‬‬
−34.98%
‪‪33.57 B‬‬
−13.84%
‪‪35.90 B‬‬
−23.56%
‪‪38.58 B‬‬
−21.36%
‪‪41.75 B‬‬
+10.92%
‪‪39.30 B‬‬
+17.05%
‪‪155.53 B‬‬
‪‪−26.36 B‬‬
‪‪−26.57 B‬‬
‪‪−23.97 B‬‬
‪‪−22.67 B‬‬
‪‪−23.66 B‬‬
‪‪−23.75 B‬‬
‪‪−24.88 B‬‬
‪‪−24.27 B‬‬
‪‪−96.57 B‬‬
Gross profitYoY growth
‪‪20.61 B‬‬
−47.25%
‪‪22.48 B‬‬
+26.86%
‪‪13.67 B‬‬
−52.86%
‪‪10.90 B‬‬
−33.12%
‪‪12.24 B‬‬
−40.60%
‪‪14.83 B‬‬
−34.05%
‪‪16.86 B‬‬
+23.37%
‪‪15.03 B‬‬
+37.80%
‪‪58.96 B‬‬
‪‪−17.95 B‬‬
‪‪−21.03 B‬‬
‪‪−17.35 B‬‬
‪‪−15.55 B‬‬
‪‪−15.14 B‬‬
‪‪−17.64 B‬‬
‪‪−16.20 B‬‬
‪‪−15.15 B‬‬
‪‪−64.12 B‬‬
‪‪2.66 B‬‬
−89.69%
‪‪1.45 B‬‬
‪‪−3.68 B‬‬
−132.53%
‪‪−4.64 B‬‬
−296.69%
‪‪−2.90 B‬‬
−208.83%
‪‪−2.81 B‬‬
−293.37%
‪‪668.07 M‬‬
‪‪−120.12 M‬‬
+97.41%
‪‪−5.16 B‬‬
‪‪86.04 M‬‬
‪‪92.47 M‬‬
‪‪244.42 M‬‬
‪‪278.03 M‬‬
‪‪−117.39 M‬‬
‪‪53.60 M‬‬
‪‪−450.22 M‬‬
‪‪−48.81 M‬‬
‪‪−562.81 M‬‬
Pretax incomeYoY growth
‪‪2.75 B‬‬
−89.46%
‪‪1.55 B‬‬
‪‪−3.44 B‬‬
−131.33%
‪‪−4.36 B‬‬
−310.48%
‪‪−3.01 B‬‬
−209.70%
‪‪−2.76 B‬‬
−278.34%
‪‪217.84 M‬‬
‪‪−168.92 M‬‬
+96.13%
‪‪−5.72 B‬‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪‪−1.02 B‬‬
‪‪−1.04 B‬‬
‪‪−29.59 M‬‬
‪‪90.47 M‬‬
‪‪102.45 M‬‬
‪‪−246.34 M‬‬
‪0.00‬
‪‪1.11 B‬‬
‪‪965.09 M‬‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪‪1.73 B‬‬
‪‪505.09 M‬‬
‪‪−3.47 B‬‬
‪‪−4.27 B‬‬
‪‪−2.91 B‬‬
‪‪−3.01 B‬‬
‪‪217.84 M‬‬
‪‪940.04 M‬‬
‪‪−4.76 B‬‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
Net incomeYoY growth
‪‪1.73 B‬‬
−90.32%
‪‪505.09 M‬‬
+53.94%
‪‪−3.47 B‬‬
−141.25%
‪‪−4.27 B‬‬
−310.80%
‪‪−2.91 B‬‬
−268.16%
‪‪−3.01 B‬‬
−694.96%
‪‪217.84 M‬‬
‪‪940.04 M‬‬
‪‪−4.76 B‬‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪‪1.73 B‬‬
‪‪505.09 M‬‬
‪‪−3.47 B‬‬
‪‪−4.27 B‬‬
‪‪−2.91 B‬‬
‪‪−3.01 B‬‬
‪‪217.84 M‬‬
‪‪940.04 M‬‬
‪‪−4.76 B‬‬
‪1.39‬
−90.32%
‪0.40‬
+53.94%
‪−2.77‬
−141.25%
‪−3.42‬
−310.80%
‪−2.33‬
−268.16%
‪−2.40‬
−694.93%
‪0.17‬
‪0.75‬
‪−3.81‬
‪1.39‬
−90.32%
‪0.40‬
+53.94%
‪−2.77‬
−141.25%
‪−3.42‬
−310.80%
‪−2.33‬
−268.16%
‪−2.40‬
−694.93%
‪0.17‬
‪0.75‬
‪−3.81‬
‪‪1.25 B‬‬
‪‪1.25 B‬‬
‪‪1.25 B‬‬
‪‪1.25 B‬‬
‪‪1.25 B‬‬
‪‪1.25 B‬‬
‪‪1.25 B‬‬
‪‪1.25 B‬‬
‪‪1.25 B‬‬
‪‪1.25 B‬‬
‪‪1.25 B‬‬
‪‪1.25 B‬‬
‪‪1.25 B‬‬
‪‪1.25 B‬‬
‪‪1.25 B‬‬
‪‪1.25 B‬‬
EBITDAYoY growth
‪‪6.51 B‬‬
−76.39%
‪‪4.65 B‬‬
‪‪81.90 M‬‬
−99.43%
‪‪−925.71 M‬‬
−116.66%
‪‪752.20 M‬‬
−88.44%
‪‪691.54 M‬‬
−85.11%
‪‪4.32 B‬‬
+5,171.41%
‪‪3.56 B‬‬
‪‪9.33 B‬‬
EBITYoY growth
‪‪2.66 B‬‬
−89.69%
‪‪1.45 B‬‬
‪‪−3.68 B‬‬
−132.53%
‪‪−4.64 B‬‬
−296.69%
‪‪−2.90 B‬‬
−208.83%
‪‪−2.81 B‬‬
−293.37%
‪‪668.07 M‬‬
‪‪−120.12 M‬‬
+97.41%
‪‪−5.16 B‬‬
‪‪−44.31 B‬‬
‪‪−47.60 B‬‬
‪‪−41.32 B‬‬
‪‪−38.22 B‬‬
‪‪−38.80 B‬‬
‪‪−41.39 B‬‬
‪‪−41.08 B‬‬
‪‪−39.42 B‬‬
‪‪−160.69 B‬‬